See the evidence of continuous control DUPIXENT has the potential to improve the management of moderate-to-severe atopic dermatitis.1View the Results
DUPIXENT is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.
Connect with a DUPIXENT Field Representative to get answers to any product-related questions you might have.Contact a Rep
A total of 917 adult patients in Trials 1 and 2 (16-week trials) and 421 adult patients in Trial 3 (52-week trial) with moderate-to-severe atopic dermatitis not adequately controlled with topical treatments were randomized to DUPIXENT 300 mg Q2W or placebo. For all patients in Trial 3, lesions were treated with concomitant topical corticosteroids (TCS). Eligible patients had an IGA score ≥3 (overall atopic dermatitis lesion severity scale of 0 to 4), EASI score ≥16 on a scale of 0 to 72, and body surface area involvement of ≥10%. At baseline, 52% of subjects had an IGA score of 3 (moderate atopic dermatitis), 48% of subjects had an IGA of 4 (severe atopic dermatitis), mean EASI score was 33 and weekly averaged peak pruritus NRS was 7 on a scale of 0 to 10. The primary endpoint for all three trials was the change from baseline in the proportion of subjects with an IGA 0 (clear) or 1 (almost clear) and ≥2-point improvement at Week 16. Other endpoints included the change from baseline in the proportion of subjects with EASI-75 (improvement of ≥75%) and reduction in itch as defined by ≥4-point improvement in the peak pruritus NRS.1
38% and 36% of DUPIXENT patientsa in 2 pivotal studies (Trials 1 and 2) achieved clear or almost-clear skin (IGA 0 or 1) at Week 16 vs 10% and 9% with placeboa (P<0.001)1,2,b
39% and 36% of DUPIXENT patientsa achieved clear or almost-clear skin with DUPIXENT + TCSa at 16 weeks and 52 weeks vs 12% and 13% with placebo + TCSa , respectively in Trial 3 (P<0.0001)1,3,bView the Results
51% and 44% of patients treated with DUPIXENTa experienced at least 75% improvement in EASI (EASI-75) in 2 pivotal studies (Trials 1 and 2) at Week 16 vs 15% and 12% with placebo (P<0.001). Similar results were seen in Trial 3 (concomitant use with TCS)1,2,aSee the Consistent Proof
51% of patients experienced long-term itch reduction (≥4-point improvement on the peak pruritus NRS) at Week 52 with DUPIXENT + TCSa vs 13% with placebo + TCSa (P<0.0001) in Trial 3. Significant reduction of itch occurred as early as Week 21,3See the Data
The most common adverse reactions through Week 16 (incidence ≥1%) are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, and dry eye. The safety profile of DUPIXENT + TCS through Week 52 (Trial 3) was generally consistent with the safety profile observed at Week 16.1Review the Safety Profile
EASI, Eczema Area and Severity Index; IGA, Investigator's Global Assessment; NRS, numerical rating scale; QW, once every week; Q2W, once every 2 weeks; TCS, topical corticosteroids.
DUPIXENT may be an appropriate treatment
for your adult patients with uncontrolled
moderate-to-severe atopic dermatitis.